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Mark C. Knouse, MD, Yennifer Lopez, Hope Kincaid, MPH and Shae Duka, BS 
Lehigh Valley Health Network, Allentown, Pa.
INTRODUCTION
•  Last year the National Travel and Tourism Office 
estimated that 93,000,000 US travelers went 
abroad.1 
•  Missed opportunities for vaccination in the higher 
risk group of travelers may result in increased 
disease rates in this population.
•  A previous study looking at GTEN2 travel clinics 
noted that 28% of travelers had refused at least one 
recommended vaccine.3
•  As a quality initiative to improve vaccination rates at 
our travel clinic, we sought to determine if there might 
be an association between the traveler’s medical 
coverage and acceptance of recommended vaccines.
ABSTRACT 
Background: Every year increasing numbers of US 
travelers, including older/compromised individuals, are 
traveling abroad. Many are at increased risk for 
vaccine preventable diseases. Insurance plans typically 
cover routine immunizations but do not cover many 
travel vaccines. Little data has been published 
regarding rates of vaccine acceptance as related to 
traveler’s medical insurance, specifically the likelihood 
of accepting vaccine recommendations at the time of 
a pre-travel visit. 
Objective: We sought to describe the relationship 
between a traveler’s medical insurance and the 
likelihood of accepting vaccination recommendations 
at the time of pre-travel visit. 
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CONCLUSIONS AND NEXT STEPS
•  This review shows that 31.9% of patients declined at 
least one recommended vaccine at the time of their 
pre-travel visit. Many commonly recommended vaccines 
were refused at the time of visit (e.g. Hepatitis A, Tdap). 
•  The declination of vaccines may be predicted to some 
extent based on the traveler’s medical insurance and 
the vaccines offered.
•  The reasons given (see QRS link) for individual 
vaccines seem to vary greatly, but the end 
result is a missed opportunity for vaccination 
for this at-risk population. 
Methods: As a QI project, we reviewed existing billing 
records in comparison to vaccines ordered by the pro-
viders, between 1/4/16 – 12/29/16. Travel Medicine 
notes were retrieved, all vaccine recommendations 
were collated2 and matching billing information was 
 reviewed. 
Results: A total of 696 patients were included in the 
sample. Slightly more than half (58.3%) were female 
and the median age was 45 years. There were 1,628 
vaccines recommended with an average of 2.3 per 
traveler. Of the 658 travelers with a recommended 
vaccine, 31.9% declined at least one recommended 
vaccine. Reasons for declining were [N (%)]: not being 
concerned about the risk of illness 122(58.1), concerns 
about cost 72(34.3), referral to PCP 12(5.7), and 
contraindication 4(1.9). The insurance type with the 
highest rate of overall vaccine acceptance was 
Commercial (Non-HMO) 1,011(85.2) followed by 
Medicare HMO 19(76), Medicare 130(71.4), Self-Pay 
53(67.9), Medicaid HMO 12(54.5) and HMO 69(51.5). 
Compared with other insurance types, Self-pay and 
HMO insured travelers had lower rates of vaccine 
acceptance, except for Typhoid and Yellow Fever. The 
vaccine with the lowest acceptance rates was Rabies. 
Conclusion: Our QI project showed that vaccine 
acceptance rates varied based on the specific vaccine 
recommended and insurance coverage. It is not known 
whether some of these travelers ultimately received 
recommended vaccines elsewhere – future studies to 
explore this would be helpful to optimize the overall 
health of our travelers.
•  Typhoid fever vaccine and yellow fever vaccine are 
more often accepted regardless of the insurance.
•  Rabies vaccine was declined often and across all 
insurance types. 
•  We will plan to use this information in our pre-visit 
planning to find better ways of increasing vaccine 
acceptance based on the type of insurance.
•  Ultimately payers might use such data to create better 
systems for preventative health care in vulnerable travelers.
LIMITATIONS
•  Limitations of this review were that it was performed in 
a single center enrolled in the Global TravEpiNet2 –
results may not be generalizable to other centers.
•  We did not collect any follow-up data and were unable 
to assess whether the travelers who declined ultimately 
got their vaccines elsewhere. This is worthy of future 
investigation.
•  There are likely other reasons besides insurance 
coverage that impact a patients decision to decline  
a recommended vaccine but that data was not 
assessed as part of this initiative. 
RESULTS











Medicaid HMO  
(N=14)
Age (yrs.) 29 (21-46) 41 (23-56) 29 (21-52) 69 (66-72) 71 (66.5-76) 20.5 (17.75-28.75)
Male 13 (44.8) 217 (42.3) 15 (33.3) 39 (45.3) 6 (66.7) 0 (0)
Female 16 (55.2) 296 (57.7) 30 (66.7) 47 (54.7) 3 (33.3) 14 (100)
N= # of patients in each group Age is presented with the median and IQR
TABLE 2. OVERALL REFUSAL VS. ACCEPTANCE RATE BY 



















Vaccine Acceptance Rate 1,294 (79.5) 53 (67.9) 1,011 (85.2) 69 (51.5) 130 (71.4) 19 (76) 12 (54.5)
Vaccine Decline Rate 334 (20.5) 25 (32.1) 176 (14.83) 65 (48.5) 52 (28.6) 6 (24) 10 (45.5)
Not concerned about  
risk of illness 193 (57.8) 12 (48) 130 (74) 16 (24.6) 31 (59.6) 4 (66.7) 0
Concerned about cost 110 (32.9) 9 (36) 38 (21.6) 38 (58.5) 19 (36.5) 2 (33.3) 4(40)
Contraindicated 4 (1.2) 0 2 (1.1) 0 2 (3.8) 0 0
Referred to PCP 27 (8.1) 4 (16) 6 (3.4) 11 (16.9) 0 0 6 (60)
NOTE: Unit of analysis is patient, those who declined one or more recommended vaccines included.
REASONS FOR DECLINING RECOMMENDED VACCINES (N=210)*
■Accepted 68.1%
■Declined 31.9%
■Not concerned about risk of illness 58.1%
■Concerns about cost 34.3%
■Contraindication 1.9%




































































ACCEPTANCE OF VACCINE BY INSURANCE TYPE
Yellow FeverTyphoidPneumoniaTdap
Japanese EncephalitisMeningitisFluHepA
*Self-Pay (n=20), Commercial (n=287), HMO (n=29), 
Medicare (n=42), Medicare HMO (n=7), Medicaid HMO (n=3)
*Self-Pay (n=10), Commercial (n=121), HMO (n=10), 
Medicare (n=16), Medicare HMO (n=2), Medicaid HMO (n=1)
*Self-Pay (n=6), Commercial (n=107), HMO (n=9), Medicare (n=6), 
Medicare HMO (n=2), Medicaid HMO (n=0)
*Self-Pay (n=1), Commercial (n=7), HMO (n=5), 
Medicare (n=4), Medicare HMO (n=0), Medicaid HMO (n=0)
*Self-Pay (n=2), Commercial (n=13), HMO (n=8), 
Medicare (n=5), Medicare HMO (n=0), Medicaid HMO (n=1)
*Self-Pay (n=25), Commercial (n=447), HMO (n=41), 
Medicare (n=69), Medicare HMO (n=8), Medicaid HMO (n=9)
*Self-Pay (n=0), Commercial (n=28), HMO (n=6), 
Medicare (n=10), Medicare HMO (n=2), Medicaid HMO (n=0)
*Self-Pay (n=11), Commercial (n=100), HMO (n=16), 
Medicare (n=13), Medicare HMO (n=1), Medicaid HMO (n=7)
patients had at least 1 vaccine 
recommended, with a rate of 2.5 



















NOTE: N/A means that specific vaccine was not recommended for any patient with that insurance type.
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